The impact of the origin of surgical sperm retrieval on placental and embryonic development: The Rotterdam Periconception cohort

Jeffrey Hoek1 | Willem P. A. Boellaard2 | Eva S. van Marion1 | Sten P. Willemsen1,3 | Esther.B. Baart1 | Régine P. M. Steegers-Theunissen1 | Sam Schoenmakers1

1Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
2Department of Urology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
3Department of Biostatistics, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands

Correspondence
Régine P. M. Steegers-Theunissen, Department of Obstetrics and Gynecology, Erasmus MC, University Medical Center, Wytemaweg 80, 3015 CN Rotterdam, The Netherlands. Email: r.steegers@erasmusmc.nl

Funding information
This research was funded by the department of Obstetrics and Gynecology of the Erasmus MC, University Medical Center, Rotterdam, the Netherlands.

Abstract

**Background:** In patients with azoospermia, pregnancy can be achieved after surgical techniques using sperm retrieved from the testis or epididymis, which can impact on DNA integrity and epigenetics. DNA of the fetus and placenta is equally derived from both parents; however, genes important for placental development are expressed from the paternal alleles. Therefore, the origin of sperm may affect fetal and placental development.

**Objectives:** To investigate whether first-trimester trajectories of embryonic and placental development of pregnancies conceived after intracytoplasmic sperm injection (ICSI) with testicular sperm extraction (TESE) or microsurgical epididymal sperm aspiration (MESA), are different from pregnancies after ICSI with ejaculated sperm or natural conceptions.

**Materials and methods:** A total of 147 singleton ICSI pregnancies, including pregnancies conceived after TESE (n = 23), MESA (n = 25) and ejaculated sperm (n = 99), and 380 naturally conceived and 140 after IVF treatment without ICSI were selected from the prospective Rotterdam periconception cohort. Crown-rump length (CRL), embryonic volume (EV), Carnegie stages, and placental volume (PV) at 7, 9, and 11 weeks of gestation were measured using 3D ultrasound and virtual reality technology.

**Results:** Linear mixed model analysis showed no differences in trajectories of CRL, EV, and Carnegie stages between pregnancies conceived after ICSI with testicular, epididymal, and ejaculated sperm. A significantly positive association was demonstrated for PV between pregnancies conceived after TESE-ICSI (adjusted beta: 0.28(95%CI: 0.05-0.50)) versus ICSI with ejaculated sperm. Retransformation to original values showed that the PV of pregnancies after TESE-ICSI is 14.6% (95%CI: 1.4%-25.5%) larger at 11 weeks of gestation compared to ICSI pregnancies conceived with ejaculated sperm.

**Discussion and Conclusion:** Here we demonstrate that the first-trimester growth trajectory of the placenta is increased in pregnancies conceived after TESE-ICSI compared to those conceived after ICSI with ejaculated sperm. Findings are discussed in...
1 | INTRODUCTION

Male factor subfertility is an increasing problem due to aging, obesity, and poor lifestyle, which can often be treated with lifestyle interventions. In severe male factor subfertility, however, intracytoplasmic sperm injection (ICSI) is often successfully used to achieve pregnancy. Sperm used for assisted reproductive treatment (ART) can have different origins dependent on the underlying cause or diagnosis of the male factor. In cases of non-obstructive azoospermia (NOA) sperm can be retrieved surgically by testicular sperm extraction (TESE). TESE can also be performed in the case of post-vasectomy, iatrogenic, congenital or post-infectious obstructive azoospermia (OA), or when vasovasostomy or microsurgical epididymal sperm aspiration (MESA) failed. In both cases the sperm is not (TESE) or only partially (MESA) transported through the epididymis. It is becoming increasingly clear that this transport through the epididymis is a key factor in sperm maturation and functioning. The epididymis secretes epididymal specific proteins, hormones, small non-coding RNAs and these factors combined can influence sperm epigenetics, gene expression and modify the sperm surface. Although testicular sperm has not entered the anatomical part of the epididymis, it has the ability to activate the oocyte after ICSI. However, testicular sperm morphological quality is usually low and several studies indicate that the incidence of chromosomal abnormalities is increased in testicular sperm. These abnormalities are associated with a decreased chance of implantation and lower ongoing pregnancy rates, possibly due to an increased aneuploidy rate in embryos. However, a recent study in more than 340,000 IVF/ICSI cycles showed no clinical differences between pregnancies conceived with testicular, epididymal or ejaculated sperm regarding pregnancy rate and full-term delivery. To overcome issues of timing and multiple surgical procedures for men, sperm can also be cryopreserved and thawed for later use. Several studies show similar treatment outcomes between fresh and frozen sperm.

The period of embryonic and placental growth in the first trimester of pregnancy is characterized by rapid cell multiplication and therefore vulnerable for alterations in both maternal- and paternal-originated DNA integrity and epigenetic (re)programming. Interestingly, paternally imprinted genes are predominantly expressed in the placenta. Embryonic and placental growth can be reliably measured using three-dimensional ultrasound (3D-US) techniques in combination with virtual reality technology. This combination allows in-depth perception and assessment of growth by measuring crown-rump length (CRL) and embryonic volume (EV). Furthermore, it is possible to make an accurate assessment of the Carnegie stage based on internal and external morphological characteristics, as a marker of embryonic development.

Since there are a number of differences regarding chromosomal constitution and epigenetics between sperm retrieved after TESE and MESA as compared to ejaculated sperm combined with a large preferential paternal expression profile of the placental genome, we hypothesize that embryonic and placental growth and development might differ between these groups. The aim of this study is to investigate whether placental and embryonic growth trajectories of ICSI pregnancies conceived with TESE and MESA are different from pregnancies after ICSI with ejaculated sperm, IVF or naturally conceived.

2 | MATERIALS AND METHODS

2.1 | Ethical approval

This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving patients were approved by the Medical Ethical and Institutional Review Board of the Erasmus MC, University Medical Centre, Rotterdam, the Netherlands (MEC-2004-227). Written informed consent was obtained from all female and male participants at enrollment.

2.2 | Study population

Participants selected for this study were enrolled in the Rotterdam Periconception Cohort (Predict study). This is an ongoing open prospective tertiary hospital-based cohort embedded in the outpatient clinic of the Department of Obstetrics and Gynecology of the Erasmus MC, University Medical Center Rotterdam, the Netherlands. The design of the cohort study has previously been published. Women and their partners were eligible for inclusion if they were at least 18 years of age and had an ongoing intrauterine singleton pregnancy and were less than 10 + 0 weeks of gestational age (GA). Participants were recruited for inclusion from November 2010 onwards.

For the current analysis, we included pregnancies of women who conceived after ICSI in combination with testicular, epididymal, cryopreserved or ejaculated sperm. For a general reference group, we included pregnancies of women who conceived through

**KEYWORDS**

fertilization in vitro, placenta, spermatozoa, testicular sperm, trophoblast
IVF with ejaculated sperm and women who conceived naturally. GA was either based on the exact conception date for ICSI and the reported last menstrual period for naturally conceived pregnancies. We excluded pregnancies conceived after using donor semen or oocyte donation, and pregnancies complicated by congenital malformations and intrauterine fetal demise. Furthermore, we excluded pregnancies of women with an irregular menstrual cycle (menstrual cycle of less than 25 days or more than 31 days) or from which no first day of the last menstrual period was known, since in these pregnancies GA is based on CRL, which is our main outcome parameter.

2.3 | Sperm retrieval

Men with non-obstructive azoospermia (NOA) all underwent TESE. In general, an obstructive component was excluded on medical history, physical examination, reproductive hormones (luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone) and scrotal ultrasound. Karyotyping and Y-chromosomal microdeletions were determined in all of these patients. All men with a diagnosed obstructive azoospermia (OA) initially underwent MESA. When motile sperm were microscopically detected, sperm cryopreservation was performed. When no motile sperm was found, TESE was performed. The latter group was excluded for analysis to create a homogenous TESE-ICSI group with only NOA patients.

TESE was performed under local anesthesia with a standard bilateral open surgical biopsy technique. A transverse two centimeter scrotal incision was made, the tunica albuginea was incised for one centimeter (cm) and a small fragment (approximately 1.5 cm$^3$) of testicular tissue was dissected using sterile glass slides. The collected tissue was subsequently minced and the resulting spermatogenic cell suspension was washed with HEPES-HTF, followed by centrifugation at 900 g (Thermo Scientific Centrifuge) for 10 minutes. The pellet was resuspended in one ml HEPES-HTF and subsequently diluted 1:1 with cryoprotectant (Test Yolk Buffer, Irvine Scientific, United States of America). When in 1 microliter suspension in 250 fields of view (FOV) at least one normal spermatozoa was found, cryopreservation was performed in straws (Cryo Bio System™, Irvine Scientific, United States of America) by placing them in liquid nitrogen vapor. Semen cryopreservation was always performed prior to spermatoxic treatment.

2.4 | Ovarian stimulation and embryo culture

Ovarian stimulation was performed by either a GnRH agonist or antagonist followed by recombinant follicle-stimulating hormone (FSH). Human chorionic gonadotrophin or a GnRH agonist were used as a trigger for final maturation of the oocyte and ovulation. Testicular, epididymal, and cryopreserved sperm were thawed and the sperm cells with best morphological and motile characteristics were selected for oocyte injection. After ovum pickup, the collected oocytes were injected with either frozen-thawed testicular, epididymal or cryopreserved sperm or fresh ejaculated sperm. For the IVF treatment, fresh ejaculated sperm was washed and added to the dishes with oocytes.

All inseminated oocytes were cultured in G-1 PLUS cleavage stage medium ([Vitrolife, Goteborg, Sweden] between January 2010 and November 2014 and SAGE 1-StepTM medium [Origo/Cooper Surgical] from December 2014 onwards. All inseminated oocytes were cultured at 36.8 degrees Celsius with 7% oxygen and 5% carbon dioxide. The transfer of fresh embryos was performed on day 3 and the supernumerary embryos were cultured until day 4 and then cryopreserved. If a cryopreserved embryo was transferred, embryos were thawed and cultured overnight and transferred the following day corresponding to day 5 of embryo development.

2.5 | Study parameters

Baseline characteristics and obstetric history were retrieved through self-administered questionnaires covering details on age, ethnicity, and educational level. All data were verified at study entry by a researcher. Anthropometrics were measured by a researcher at study entry. Smoking and alcohol were defined as any consumption during the periconception period. Details regarding subfertility diagnoses, method of sperm retrieval and whether IVF or ICSI was used, were retrieved from the electronic patient files.

2.6 | Ultrasound data

From November 2010 onwards women underwent three transvaginal ultrasounds, in the 7th, 9th, and 11th week of gestation. Ultrasound scans were performed with a 6-12 MHz transvaginal probe using GE Voluson E8 equipment and 4D View software (General Electrics Medical Systems, Zipf, Austria).

To optimally make use of the depth information present in 3D-ultrasound data, images were transferred to our Barco I-Space...
(a Cave Automatic Virtual Environment–like virtual reality system). In the Barco I-space, an interactive virtual reality hologram, which allows depth perception, was created. All measurements were performed by trained research staff.

2.7 | Outcome variables

Outcome variables were generated multiple times in the first trimester of pregnancy, which gives the opportunity to study growth trajectories over time. CRL was measured three separate times per time point and embryo, and the mean of these measurements was used for analysis. EV measurements were performed once at each time point per embryo using a semi-automatic method based on gray levels. Carnegie stages were determined once per time point to assess external morphological features of the embryo such as the development of the limbs and the curvature of the embryo, according to the protocol which was published previously. Placental volume (PV) in first trimester, also known as trophoblast volume, was measured once per time point per pregnancy using Virtual Organ Computer-aided Analysis (VOCAL) (TM; GE Medical Systems, Zipf, Austria). In short, twelve sections of the placenta were obtained using a rotational step of 15°. Trophoblast and myometrium can be distinguished by their difference in echogenicity, thereby calculating the total pregnancy volume. The volume of the placenta can be calculated by subtracting the gestational sac volume from the total pregnancy volume.

2.8 | Statistical analysis

To take the correlation between measurements of the same pregnancy into account, we used a linear mixed model. In the first trimester of pregnancy, we used this linear mixed model to assess the associations between the different origins of sperm and CRL, EV, Carnegie stage, and PV.

Furthermore, we used naturally conceived pregnancies and pregnancies after IVF with ejaculated sperm as a reference group for the different origins of sperm for ICSI.

For analysis, we used a square root transformation for the CRL measurements and a third root transformation for the EV and PV measurements, which led to linearity with GA. Carnegie stages were not transformed and used as continuous variable. For the graphs showing the EV and PV trajectories, the modelled EV and PV were retransformed to the original values.

In the first model, we adjusted for GA only. In the second model, we additionally adjusted for the paternal covariables age, smoking and alcohol use and maternal parity selected based on the characteristics of the study groups and literature.

p-values < 0.05 were considered statistically significant. All analyses were performed using SPSS package 24.0 (IBM SPSS Statistics, Armonk, NY).

3 | RESULTS

3.1 | Baseline

From a total of 1,743 pregnant women included in the cohort, 1,289 participated together with their male partner. Due to missing ultrasound data and women who did not undergo a first-trimester ultrasound, 213 pregnancies were excluded. Furthermore, we excluded pregnancies because of miscarriage (n = 87), oocyte donation (n = 5), congenital malformations (n = 18), intrauterine fetal death (n = 10), and termination of pregnancy (n = 11) and cases with an irregular menstrual cycle prior to natural conception (n = 257). The remaining 688 included pregnancies comprised of 380 naturally conceived pregnancies, 140 pregnancies after IVF, and 168 pregnancies after ICSI. Of the included ICSI pregnancies, 28 were conceived after ICSI with TESE sperm. Five patients were excluded because of an obstructive azoospermia. The included 23 patients all underwent TESE because of a non-obstructive azoospermia. In the ICSI pregnancy group, 25 resulted after ICSI with MESA sperm, 16 with cryopreserved sperm and 99 with freshly ejaculated sperm (Figure 1). There are no significant differences regarding the distribution of the origin of the sperm between pregnancies complicated by congenital malformations and pregnancies without congenital malformations (P = .09) and between pregnancies complicated by intra uterine fetal demise and pregnancies without intra uterine fetal demise (P = .73) (data not shown).

At baseline, there were no significant differences regarding paternal age, BMI, geographical background, education, alcohol use, and smoking between the different ICSI groups. Paternal age was significantly lower in the naturally conceived pregnancy group compared to the IVF group (33.6 vs 36.2 year respectively (P < .01) (Table 1). Regarding maternal factors at baseline, we found no statistical differences for age, BMI, geographical origin, education, and alcohol use. There was a significant difference regarding parity, where the percentage nulliparous in the naturally conceived group was lower compared to all other groups (P < .001).

Of the included pregnancies resulting after TESE-procedures, the indication for ICSI treatment was because of either male (82.6%) or combined male–female factor subfertility (17.4%), with 100% being a non-obstructive azoospermia (Table S1).

No differences were seen regarding the embryonic growth parameters CRL and EV when comparing the TESE and MESA-ICSI groups with freshly ejaculated sperm-ICSI (Table 2 and Figure 2B). Also, when comparing TESE-ICSI with naturally conceived pregnancies, EV trajectories were not different (Model 2: TESE-ICSI beta: 0.06 (95% confidence interval (CI): -0.01 to 0.13)) (Table 3 a). A significantly positive association was found for Model 1 regarding embryonic development estimated in Carnegie stages when comparing MESA-ICSI with ICSI with freshly ejaculated sperm (beta: 0.38 (95%CI: 0.02 to 0.74)); however, this effect attenuated after correction for confounders (beta: 0.17 (95%CI: −0.18 to 0.52)) (Table 2).

Model 1 showed a significantly positive association (beta: 0.23 (95% confidence interval (CI): 0.02 to 0.44)) regarding PV in the
TESE-ICSI group when compared to ICSI with freshly ejaculated sperm (Table 2). After adjustment for paternal covariates age, smoking, alcohol, and maternal parity (Model 2) the significantly positive association remains (beta: 0.28 (95%CI: 0.05 to 0.50)). Retransformation of the betas to the original values showed that PVs of pregnancies after TESE-ICSI are 14.6% (95%CI: 1.4% to 25.5%) larger at 11 weeks of gestation as compared to pregnancies after fresh ejaculated-ICSI (Figure 2A).

To investigate the effect of cryopreservation, we pooled the groups with TESE and MESA treatment and cryopreserved sperm, and compared them with the group of ICSI with freshly ejaculated sperm. Again, we found no statistically significant differences regarding trajectories of CRL, EV, PV, and Carnegie stage (Table 3 b).

4 | DISCUSSION

In this study, we show that pregnancies conceived after TESE-ICSI compared with ejaculated sperm-ICSI are associated with trajectories of increased PV in the first trimester of pregnancy, with an
| Conception mode                  | ICSI with TESE sperm N = 23 | ICSI with MESA sperm N = 25 | ICSI with cryo sperm N = 16 | ICSI with freshly ejaculated sperm N = 99 | p-value Differences over the ICSI groups | p-value Differences between all the groups |
|---------------------------------|-----------------------------|-----------------------------|-----------------------------|-------------------------------------------|-----------------------------------------|-------------------------------------------|
| **Men**                         |                             |                             |                             |                                           |                                         |                                           |
| Age, years median (IQR)         | 32.8 (29.9-36.5)            | 36.3 (32.9-41.8)            | 35.2 (30.6-38.1)            | 35.2 (32.1-38.6)                         | 0.08                                    | 36.2 (32.6-39.9)                           |
| BMI (measured), kg/m² median (IQR) | 26.2 (22.4-29.1)          | 27.3 (23.9-29.9)            | 26.6 (22.8-31.2)            | 26.5 (24.4-28.4)                         | 0.59                                    | 26.0 (24.0-28.6)                           |
| Geographical origin             |                             |                             |                             |                                           |                                         |                                           |
| Western, n (%)                  | 18 (78.3%)                  | 19 (76.0%)                  | 15 (93.8%)                  | 86 (86.9%)                               | 0.31                                    | 108 (77.1%)                               |
| Non-Western, n (%)              | 5 (21.7%)                   | 6 (24.0%)                   | 1 (6.3%)                    | 13 (13.1%)                               |                                         | 32 (22.9%)                                |
| **Education**                   |                             |                             |                             |                                           |                                         |                                           |
| High, n (%)                     | 10 (45.5%)                  | 9 (37.5%)                   | 8 (50.0%)                   | 40 (43.5%)                               | 0.99                                    | 65 (50.0%)                                |
| Intermediate, n (%)             | 9 (40.9%)                   | 11 (45.8%)                  | 6 (37.5%)                   | 40 (43.5%)                               |                                         | 53 (40.8%)                                |
| Low, n (%)                      | 3 (13.6%)                   | 4 (16.7%)                   | 2 (12.5%)                   | 12 (13.0%)                               |                                         | 12 (9.2%)                                 |
| Alcohol use, n (%)              | 17 (81.0%)                  | 17 (70.8%)                  | 11 (73.3%)                  | 60 (69.0%)                               | 0.75                                    | 94 (75.2%)                                |
| Smoking, n (%)                  | 7 (33.3%)                   | 4 (18.2%)                   | 5 (33.3%)                   | 20 (23.0%)                               | 0.56                                    | 34 (27.2%)                                |
| **Women**                       |                             |                             |                             |                                           |                                         |                                           |
| Age, years median (IQR)         | 30 (28.1-33.2)              | 31.1 (28.8-35.7)            | 30.8 (24.5-35.2)            | 32.5 (29.5-35.0)                         | 0.09                                    | 34.6 (31.5-38.1)                           |
| BMI (measured), kg/m² median (IQR) | 24.4 (21.7-30.6)        | 22.5 (21.2-28.2)            | 25.6 (22.8-28.8)            | 24.9 (21.5-28.0)                         | 0.43                                    | 24.2 (21.7-26.6)                           |
| Parity, nulliparous, n (%)      | 18 (81.8%)                  | 17 (68.0%)                  | 12 (75.0%)                  | 70 (70.7%)                               | 0.7                                     | 94 (67.6%)                                |
| Geographical origin             |                             |                             |                             |                                           |                                         |                                           |
| Western, n (%)                  | 16 (69.6%)                  | 22 (88.0%)                  | 15 (93.8%)                  | 88 (88.9%)                               | 0.08                                    | 113 (80.7%)                               |
| Non-Western, n (%)              | 7 (30.4%)                   | 3 (12.0%)                   | 1 (6.3%)                    | 11 (11.1%)                               |                                         | 333 (87.6%)                               |
| **Education**                   |                             |                             |                             |                                           |                                         |                                           |
| High, n (%)                     | 7 (33.3%)                   | 13 (54.2%)                  | 5 (31.1%)                   | 55 (57.9%)                               | 0.12                                    | 84 (61.3%)                                |
| Intermediate, n (%)             | 12 (57.1%)                  | 9 (37.5%)                   | 11 (68.8%)                  | 33 (34.7%)                               |                                         | 45 (32.8%)                                |
| Low, n (%)                      | 2 (9.5%)                    | 2 (8.3%)                    | 0 (0.0%)                    | 7 (7.4%)                                 |                                         | 8 (5.8%)                                  |
| Alcohol use, n (%)              | 6 (30.0%)                   | 6 (24.0%)                   | 5 (33.3%)                   | 19 (19.8%)                               | 0.57                                    | 30 (22.1%)                                |
| Smoking, n (%)                  | 7 (35.0%)                   | 2 (8.0%)                    | 5 (33.3%)                   | 8 (8.3%)                                 | 0.002                                   | 14 (10.2%)                                |

**Note:** Bold indicates significant results.

Posthoc test significant differences between: ²naturally conceived and IVF, ²²TESE-ICSI and fresh ejaculated sperm, ²³TESE-ICSI and MESA-ICSI, ²⁴cryo sperm-ICSI and MESA-ICSI, ²⁵cryo sperm-ICSI and fresh ejaculated sperm, ²⁶naturally conceived and all other growth, ²⁷IVF and all other growth.

**Abbreviations:** BMI, body mass index; ICSI, intracytoplasmic sperm injection; IQR, interquartile range; IVF, in vitro fertilization; MESA, microsurgical epididymal sperm aspiration; TESE, testicular sperm extraction.
**Table 2** Betas of embryonic development (CRL, EV, Carnegie stages) and placental growth trajectories (PV) of different origins of sperm retrieval compared to ICSI with ejaculated sperm

|                  | Model 1 |                  | Model 2 |                  |
|------------------|---------|------------------|---------|------------------|
|                  | CRL     | EV               | Carnegie| PV               |
| ICSI with ejaculated sperm | Beta (95% CI) | Beta (95% CI) | Beta (95% CI) | Beta (95% CI) |
| Reference        | p-value | Reference        | p-value | Reference        | p-value |
| ICSI with TESE sperm | 0.02 (-0.08 to 0.70) | 0.02 (-0.03 to 0.54) | 0.14 (-0.25 to 0.49) | 0.23 (0.02 to 0.44) |
| Reference        | p-value | Reference        | p-value | Reference        | p-value |
| ICSI with MESA sperm | 0.01 (-0.08 to 0.83) | 0.02 (-0.03 to 0.51) | 0.38 (0.02 to 0.04) | -0.01 (-0.21 to 0.93) |
| Reference        | p-value | Reference        | p-value | Reference        | p-value |
| ICSI with cryopreserved sperm | -0.002 (-0.11 to 0.98) | -0.02 (-0.06 to 0.53) | 0.21 (-0.25 to 0.37) | 0.01 (-0.27 to 0.95) |
| Reference        | p-value | Reference        | p-value | Reference        | p-value |

Note: Bold indicates significant results.

Model 1: Adjusted for gestational age. Model 2: Model 1 + adjusted for paternal age, smoking and alcohol and maternal parity.

Abbreviations: CI, confidence interval; CRL, crown-rump length; EV, embryonic volume; ICSI, intracytoplasmic sperm injection; MESA, microsurgical epididymal sperm aspiration; PV, placental volume; TESE, testicular sperm extraction.
The aim of our study was to gain more insight into the early (patho)physiology of the role of the origin of sperm and embryonic and placental development, not to study pregnancy outcomes. Our group previously showed that IVF-ICSI pregnancies exhibit larger embryonic growth compared to naturally conceived pregnancies indicating that the procedure itself can induce differences regarding embryonic development. A possible explanation for a lack of detectable effect of TESE sperm on CRL and EV, could be due to the strong impact of the IVF-ICSI procedure itself on epigenetic reprogramming of the embryo and endometrial receptivity.

Our study has several strengths and limitations. A strength is the availability of multiple serial 3-D ultrasounds in the first trimester of the same pregnancy and the possibility to precisely assess several morphogenic features of embryonic and placental growth and development. Our group previously showed that early PV can reliably be measured with very high intra-class correlation coefficients (ICC > 0.95). In the present study, we confirm other studies that showed no significant differences regarding PV between naturally conceived pregnancies and IVF-ICSI pregnancies (n = 70) (39.8 cm³ and 40.2 cm³ respectively). Moreover, unique in our study is the comparison of differences in embryonic and placental growth trajectories in subgroups of ICSI with TESE, MESA and ejaculated sperm versus IVF (with ejaculated sperm) with naturally conceived pregnancies as reference groups. Furthermore, we were able to differentiate between the effects of the cryopreservation procedure and the direct effect of TESE sperm itself by showing results of all cryopreserved sperm compared to ICSI with freshly ejaculated sperm. A limitation of our study remains a relatively low number of patients in the different subgroups. Since this study is an observational cohort, we adjusted for potential confounders; however, residual confounding cannot be fully excluded. We used self-administered questionnaires, which are verified face to face at

No effects were established regarding embryonic growth, as measured by CRL and EV, between the different sperm origins. Since paternally expressed genes are predominantly expressed in the placenta, we expected to show periconceptional paternal effects on PV trajectories. Our group previously showed that IVF-ICSI pregnancies exhibit larger embryonic growth compared to naturally conceived pregnancies indicating that the procedure itself can induce differences regarding embryonic development. Another possible explanation for a lack of detectable effect of TESE sperm on CRL and EV, could be due to the strong impact of the IVF-ICSI procedure itself on epigenetic reprogramming of the embryo and endometrial receptivity.

Our study has several strengths and limitations. A strength is the availabilty of multiple serial 3-D ultrasounds in the first trimester of the same pregnancy and the possibility to precisely assess several morphogenic features of embryonic and placental growth and development. Our group previously showed that early PV can reliably be measured with very high intra-class correlation coefficients (ICC > 0.95). In the present study, we confirm other studies that showed no significant differences regarding PV between naturally conceived pregnancies (n = 84) and IVF-ICSI pregnancies (n = 70) (39.8 cm³ and 40.2 cm³ respectively). Moreover, unique in our study is the comparison of differences in embryonic and placental growth trajectories in subgroups of ICSI with TESE, MESA and ejaculated sperm versus IVF (with ejaculated sperm) with naturally conceived pregnancies as reference groups. Furthermore, we were able to differentiate between the effects of the cryopreservation procedure and the direct effect of TESE sperm itself by showing results of all cryopreserved sperm compared to ICSI with freshly ejaculated sperm. A limitation of our study remains a relatively low number of patients in the different subgroups. Since this study is an observational cohort, we adjusted for potential confounders; however, residual confounding cannot be fully excluded. We used self-administered questionnaires, which are verified face to face at
TABLE 3  Betas of embryonic development (CRL, EV, Carnegie stages) and placental growth trajectories (PV) of different origins of sperm retrieval compared to a. naturally conceived pregnancies and b. all cryopreserved sperm compared to freshly ejaculated sperm

|                | Model 1                                      | Model 2                                      |
|----------------|----------------------------------------------|----------------------------------------------|
|                | CRL Beta (95% CI)   | p-value | EV Beta (95% CI)   | p-value | Carnegie Beta (95% CI) | p-value | PV Beta (95% CI)   | p-value |
| Naturally      | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         |
| IVF            | 0.06 (0.003 to 0.12) | 0.04 | 0.04 (0.01 to 0.06) | 0.02 | 0.21 (0.01 to 0.41) | 0.04 | -0.01 (-0.11 to 0.08) | 0.77 |
|                |                  | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         |
| ICSI with ejaculated sperm | 0.08 (0.01 to 0.14) | 0.02 | 0.05 (0.02 to 0.08) | 0.003 | 0.27 (0.05 to 0.50) | 0.02 | -0.06 (-0.17 to 0.06) | 0.34 |
|                |                  | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         |
| ICSI with TESE sperm | 0.09 (-0.03 to 0.22) | 0.13 | 0.07 (0.01 to 0.13) | 0.04 | 0.41 (-0.01 to 0.84) | 0.06 | 0.19 (-0.01 to 0.39) | 0.06 |
|                |                  | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         |
| ICSI with MESA sperm | 0.08 (-0.04 to 0.20) | 0.17 | 0.06 (0.004 to 0.12) | 0.04 | 0.65 (0.25 to 1.04) | 0.001 | -0.06 (-0.26 to 0.13) | 0.53 |
|                |                  | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         |
| ICSI with cryo sperm | 0.08 (-0.07 to 0.23) | 0.29 | 0.05 (-0.02 to 0.12) | 0.18 | 0.49 (-0.03 to 1.00) | 0.07 | -0.02 (-0.29 to 0.24) | 0.86 |
|                |                  | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         | Reference         |
| ICSI with cryo sperm (TESE, MESA and cryo) | 0.01 (-0.05 to 0.07) | 0.75 | 0.01 (-0.02 to 0.04) | 0.50 | 0.26 (-0.01 to 0.52) | 0.06 | 0.09 (-0.06 to 0.24) | 0.26 |

Note: Bold indicates significant results.
Model 1: Adjusted for gestational age. Model 2: Model 1 + adjusted for paternal age, smoking and alcohol and maternal parity.
Abbreviations: CI, confidence interval; CRL, crown-rump length; EV, embryonic volume; ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilization; MESA, microsurgical epididymal sperm aspiration; PV, placental volume; TESE, testicular sperm extraction.
the first consultation by a trained research nurse, to obtain information regarding baseline variables. Social desirable answers can be expected regarding smoking and alcohol use. However, because of an expected random effect on both patient groups suffering from subfertility, we assume that confounding of the effect estimates is limited. In epidemiology, observational studies are performed as a first step for hypothesis testing and showing associations. Therefore, the results should be interpreted with causation and causality should be shown in a randomized controlled design. Our study population was recruited from a tertiary hospital. The indication for cryopreservation of sperm, for example, includes hematological or testicular cancer, which limits extrapolating of our results to a general population. Despite homogenization of the groups per different surgically retrieval procedure (only cases with NOA in the TESE group, and OA in the MESA group), other differences between groups are present, such as the cause of infertility. Since our study population is too small to correct or stratify for these factors, future larger studies should incorporate these factors in sample size calculation and analyses. Furthermore, we did not investigate birth outcomes, which was not an outcome in this study and therefore not powered accordingly.

5 | CONCLUSION

We show that placental growth trajectories in the first trimester of pregnancy are increased in pregnancies conceived after TESE-ICSI as compared to ejaculated sperm. No significant differences are shown regarding embryonic development measured as CRL, EV and Carnegie stages. These findings might be partially explained by differences in DNA damage, chromosomal constitution and epigenetics of testicular sperm as compared to ejaculated sperm. After this explorative study, future research should validate these findings in larger cohorts, including investigating possible associations with birth outcomes. Exploring the underlying pathophysiological mechanisms by measuring sperm DNA damage, placental and also the neonatal epigenome will provide insights that help optimize preconceptional health and counseling. This will help to further improve pregnancy chances and birth outcomes in subfertile couples with male factor subfertility.

ACKNOWLEDGEMENTS

The Rotterdam periconception cohort (Predict Study) is conducted by the department of Obstetrics and Gynecology at the Erasmus MC, University Medical Center, Rotterdam. We gratefully acknowledge the Predict team for data acquisition and the participating couples, gynecologists, and midwifery practices in Rotterdam for their contributions.

CONFLICT OF INTEREST

The authors report no conflicts of interest.

AUTHOR’S CONTRIBUTIONS

RST and SS initiated the research question and supervised all aspects of the study. EB was responsible for the ICSI treatment in the laboratory. JH, WB and EvM contributed to data acquisition. SW and RST supervised the statistical procedures of the manuscript. JH, WB and SS wrote the first version of the manuscript. All authors contributed to the writing and the critical revisions of the manuscript and all authors approved and authorized the final version.

ORCID

Jeffrey Hoek  https://orcid.org/0000-0003-2839-3072
Willem P. A. Boellaard  https://orcid.org/0000-0003-3623-2623
Régine P. M. Steegers-Theunissen  https://orcid.org/0000-0002-4353-5756

REFERENCES

1. Kumar N, Singh AK. Trends of male factor infertility, an important cause of infertility: A review of literature. J Hum Reprod Sci. 2015;8(4):191-196.
2. Wong WY, Thomas CM, Merkus JM, Zielhuis GA, Steegers-Theunissen RP. Male factor subfertility: possible causes and the impact of nutritional factors. Fertil Steril. 2000;73(3):435-442.
3. Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male R, Urology. Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male R, Urology. Electronic address aao. The management of obstructive azoospermia: a committee opinion. Fertil Steril. 2019;111(5):873-880.
4. Sullivan R, Mieusset R. The human epididymis: its function in sperm maturation. Hum Reprod Update. 2016;22(5):574-587.
5. Sharma U, Conine CC, Shea JM, et al. Biogenesis and function of tRNA fragments during sperm maturation and fertilization in mammals. Science. 2016;351(6271):391-396.
6. Gianaroli L, Magli MC, Cavallini G, et al. Frequency of aneuploidy in sperm from patients with extremely severe male factor infertility. Hum Reprod. 2005;20(8):2140-2152.
7. Rodrigo L, Rubio C, Peinado V, et al. Testicular sperm from patients with obstructive and nonobstructive azoospermia: aneuploidy risk and reproductive prognosis using testicular sperm from fertile donors as control samples. Fertil Steril. 2011;95(3):1005-1012.
8. Silber S, Escudero T, Lenahan K, Abdelhadi I, Kilani Z, Munne S. Chromosomal abnormalities in embryos derived from testicular sperm extraction. Fertil Steril. 2003;79(1):30-38.
9. Kawwass JF, Chang J, Boulet SL, Nangia A, Mehta A, Kissin DM. Surgically acquired sperm use for assisted reproductive technologies: trends and perinatal outcomes, USA, 2004–2015. J Assist Reprod Genet. 2018;35(7):1229-1237.
10. Cayan S, Lee D, Conaghan J, et al. A comparison of ICSI outcomes with fresh and cryopreserved epididymal spermatozoa from the same couples. Hum Reprod. 2001;16(3):495-499.
11. Kalsi J, Thum MY, Muneer A, Pryor J, Abdullah H, Minhas S. Analysis of the outcome of intracytoplasmic sperm injection using fresh or frozen sperm. BJU Int. 2011;107(7):1124-1128.
12. Frost JM, Moore GE. The importance of imprinting in the human placenta. PLoS Genet. 2010;6(7):e1001015.
13. Roussin M, Koster MPH, Mulders A, Koning AHJ, Steegers-Theunissen RPM, Steegers EA. Virtual reality imaging techniques in the study of embryonic and early placental health. Placenta. 2018;64(Suppl 1):S29-S35.
14. Verwoerd-Dikkeboom CM, Koning AH, van der Spek PJ, Exalto N, Steegers EA. Embryonic staging using a 3D virtual reality system. Hum Reprod. 2008;23(7):1479-1484.
15. Steegers-Theunissen RP, VerheijDEN-paullisen J, van Uitert EM, et al. Cohort Profile: The Rotterdam Periconceptional Cohort (Predict Study). Int J Epidemiol. 2016;45(2):374-381.
16. Rousian M, Koning AH, van Oppenraaij RH, et al. An innovative virtual reality technique for automated human embryonic volume measurements. *Hum Reprod*. 2010;25(9):2210-2216.

17. Reus AD, El-Harbachi H, Rousian M, et al. Early first-trimester trophoblast volume in pregnancies that result in live birth or miscarriage. *Ultrasound Obstet Gynecol*. 2013;42(5):577-584.

18. Xavier MJ, Roman SD, Aitken RJ, Nixon B. Transgenerational inheritance: how impacts to the epigenetic and genetic information of parents affect offspring health. *Hum Reprod Update*. 2019;25(5):518-540.

19. Hibi SE, Lough M, Keverne EB, Surani MA, Loke YW, King A. Paternal monoallelic expression of PEG3 in the human placenta. *Hum Mol Genet*. 2001;10(10):1093-1100.

20. Kim J, Frey WD, He H, et al. Peg3 mutational effects on reproduction and placenta-specific gene families. *PLoS One*. 2013;8(12):e83359.

21. Mayer W, Hemberger M, Frank H-G, et al. Expression of the imprinted genes MEST/Mest in human and murine placenta suggests a role in angiogenesis. *Dev Dyn*. 2000;217(1):1-10.

22. Minor A, Chow V, Ma S. Aberrant DNA methylation at imprinted genes in testicular sperm retrieved from men with obstructive azoospermia and undergoing vasectomy reversal. *Reproduction*. 2011;141(6):749-757.

23. Aurich C, Schreiner B, Ille N, Alvarenga M, Scarlet D. Cytosine methylation of sperm DNA in horse semen after cryopreservation. *Theriogenology*. 2016;86(5):1347-1352.

24. Zeng C, Peng W, Ding L, et al. A preliminary study on epigenetic changes during boar spermatozoa cryopreservation. *Cryobiology*. 2014;69(1):119-127.

25. Esteves SC, Roque M, Bradley CK, Garrido N. Reproductive outcomes of testicular versus ejaculated sperm for intracytoplasmic sperm injection among men with high levels of DNA fragmentation in semen: systematic review and meta-analysis. *Fertil Steril*. 2017;108(3):456-67 e1.

26. Proctor LK, Toal M, Keating S, et al. Placental size and the prediction of severe early-onset intrauterine growth restriction in women with low pregnancy-associated plasma protein-A. *Ultrasound Obstet Gynecol*. 2009;34(3):274-282.

27. Fedder J, Loft A, Parner ET, Rasmussen S, Pinborg A. Neonatal outcome and congenital malformations in children born after ICSI with testicular or epididymal sperm: a controlled national cohort study. *Hum Reprod*. 2013;28(1):230-240.

28. Oldereid NB, Hanevik Hl, Bakkevig I, et al. Pregnancy outcome according to male diagnosis after ICSI with non-ejaculated sperm compared with ejaculated sperm controls. *Reprod Biomed Online*. 2014;29(4):417-423.

29. Woldringh GH, Besselink DE, Tillema AH, Hendriks JC, Kremer JA. Karyotyping, congenital anomalies and follow-up of children after intracytoplasmic sperm injection with non-ejaculated sperm: a systematic review. *Hum Reprod Update*. 2010;16(1):12-19.

30. Eindhoven SC, van Uitert EM, Laven JS, et al. The influence of IVF/ICSI treatment on human embryonic growth trajectories. *Hum Reprod*. 2014;29(12):2628-2636.

31. Whitelaw N, Bhattacharya S, Hoad G, Horgan GW, Hamilton M, Haggarty P. Epigenetic status in the offspring of spontaneous and assisted conception. *Hum Reprod*. 2014;29(7):1452-1458.

32. Nelissen EC, Dumoulin JC, Daunay A, Evers JL, Tost J, van Montfoort AP. Placentas from pregnancies conceived by IVF/ICSI have a reduced DNA methylation level at the H19 and MEST differentially methylated regions. *Hum Reprod*. 2013;28(4):1117-1126.

33. Reus AD, Klop-van der Aa J, Rifouna MS, et al. Early pregnancy placental bed and fetal vascular volume measurements using 3-D virtual reality. *Ultrasound Med Biol*. 2014;40(8):1796-1803.

34. Churchill SJ, Wang ET, Akhlaghpour M, et al. 3rd, Pisarska MD. Mode of conception does not appear to affect placental volume in the first trimester. *Fertil Steril*. 2017;107(6):1341-1347.

35. Rifouna MS, Reus AD, Koning AH, et al. First trimester trophoblast and placental bed vascular volume measurements in IVF or IVF/ICSI pregnancies. *Hum Reprod*. 2014;29(12):2644-2649.

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section.

---

**How to cite this article:** Hoek J, Boellaard WP, Marion ES, et al. The impact of the origin of surgical sperm retrieval on placental and embryonic development: The Rotterdam Periconception cohort. *Andrology*. 2021;9:599–609. [https://doi.org/10.1111/andr.12943](https://doi.org/10.1111/andr.12943)